Comparison
DSIP vs. Sermorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Growth
CAS no.
62568-57-4
86168-78-7
Molecular weight
848.81 g/mol
3358 g/mol
Half-life
0.1 h
0.2 h
Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluYADAIFTNSYRKVLGQLSARKLLQDIMSRMechanism of action
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Sermorelin
Synthetic analogue of the first 29 amino acids of human growth-hormone-releasing hormone (GHRH). Stimulates pulsatile endogenous growth-hormone secretion from the pituitary via the GHRH receptor. Very short plasma half-life — pharmacodynamic effect lasts several hours nevertheless.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
5
of which in humans
1
3
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
1
3